Equity Details
Price & Market Data
Price: $6.32
Daily Change: -$0.13 / 2.06%
Daily Range: $6.18 - $6.47
Market Cap: $340,542,752
Daily Volume: 162,713
Performance Metrics
1 Week: 1.12%
1 Month: 0.32%
3 Months: -24.40%
6 Months: 6.76%
1 Year: 65.23%
YTD: -20.60%
About DiaMedica Therapeutics Inc. (DMAC)
Gain a deep understanding of DiaMedica Therapeutics Inc. (DMAC). The stock is trading at 6.32, showing a daily change of -$0.13 / 2.06%. Its market capitalization is 340,542,752. Performance over 1-week (1.12%) and 6-month (6.76%) periods offer valuable insights.
Company Details
Employees: 35
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.